Molecular characterization of serogroup 19 *Streptococcus pneumoniae* in the Czech Republic in the post-vaccine era

Helena Žemličková,¹²,* Lucia Mališová,¹ Petra Španělová,¹ Vladislav Jakubů,¹ Jana Kozáková,¹ Martin Musílek¹ and Matej Medvecký³

Abstract

**Purpose.** The aim of this study was to characterize serogroup 19 isolates resistant to macrolides and/or penicillin found among pneumococci recovered from cases of invasive and respiratory tract disease in the Czech Republic in 2014.

**Methods.** Pneumococcal isolates of serotypes 19A (n=26) and 19F (n=10) that were non-susceptible to penicillin and/or macrolides and had been collected in 2014 were analysed using multi-locus sequence typing (MLST). Four isolates representing the major clones were subjected to whole-genome sequencing (WGS).

**Results.** The penicillin-susceptible macrolide-resistant isolates of serotype 19A were mainly associated with sequence type (ST) 416 belonging to clonal complex (CC) 199, and the penicillin-resistant isolates were of serotype 19F belonging to ST1464 (CC 320). WGS revealed the presence of pilus 1, in association with pilus 2, in serotype 19F isolates belonging to CC 320. Another adhesin, pneumococcal serine-rich protein (PsrP), was only present in serotype 19A isolates of ST416. Analysis of the penicillin-binding proteins (PBPs) of serotype 19F penicillin-resistant isolates (ST1464 and ST271) performed on PBP1a, 2b and 2x identified a large number of mutations in comparison to the reference strain, R6. Both isolates contained a unique PBP profile; however, they were highly similar to PBP sequences of the Taiwan¹⁹F-14 reference strain. The Ppb2b sequences of both 19F isolates showed the lowest similarity to those of the Taiwan¹⁹F-14 strain (91 % similarity), while they were also found to be distantly related to each other (94 % similarity).

**Conclusions.** WGS revealed specific virulence factors in antibiotic-resistant pneumococcal clones that spread rapidly in the post-vaccine era in the Czech Republic.

**INTRODUCTION**

*Streptococcus pneumoniae* is an important pathogen of respiratory tract infections and a leading cause of bacteraemia and meningitis. The occurrence of *S. pneumoniae* that are resistant to betalactams and other groups of antibiotics complicates the effective treatment of pneumococcal infections [1]. It was predicted that the dissemination of antibiotic-resistant pneumococci would be targeted by the pneumococcal conjugate vaccines, as the serotypes included in the vaccines had accounted for the vast majority of penicillin non-susceptible serotypes [2]. After the implementation of nationwide pneumococcal vaccination for children, the incidence of invasive pneumococcal disease (IPD) has...
decreased among the vaccinated and, due to the herd effect, it has also decreased in the non-vaccinated population [3, 4]. Although a reduction in invasive disease has been reported, especially in cases caused by penicillin-resistant serotypes, the reduction of intermediate penicillin-resistant strains of vaccine serotypes has been compensated by increased intermediate resistance among non-vaccine serotypes [5–7].

The clone that has the highest impact on the spread of antibiotic resistance in the post-PCV7 era is Taiwan19F-14 [8–10]. This clone, which shows sequence type (ST) 236, was originally detected as having the 19F capsule, and was resistant to beta-lactams, macrolides and tetracyclines [11]. The surveys following the implementation of pneumococcal vaccination identified isolates belonging to this clone and showing serotype 19A in many countries in Asia and Europe, as well as in the United States [8, 12, 13]. Occasionally, 19A isolates expressing ST320, which is a double-locus variant of ST236, were found in the pre-vaccine era. After the introduction of PCV7, ST320 19A isolates have become the most prevalent multidrug-resistant genotype in the post-vaccine era in the United States and some European countries, and have continued to be identified in the PCV13 era [14–17]. In the Czech Republic, vaccination with PCV10 or PCV13 (covered by health insurance) has been included in the routine childhood immunization programme since January 2010. The use of PCV is voluntary and, according to data from the major health insurance company, 73.9% of children up to 1 year of age had been vaccinated in 2014. In the post-PCV era, isolates of the 19A serotype that are non-susceptible to penicillin and/or macrolides and tetracyclines have started to occur in carriage and respiratory samples and have also been found in IPD cases in all age cohorts [18]. The historical pre-vaccine antibiotic-resistant 19A isolates identified in the Czech Republic belonged to two clones, Hungary19A-6 and CSR19A-11 [19]. Isolates of the Taiwan19F-14 clone were not found in our environment in either serotype 19A or 19F isolates, which were mainly associated with ST423 [20]. Since the mid-1990s, serotype 9V, represented by the Spain9V-3 clone, has replaced serotype 19A (the Hungary19A-6 clone), and the total prevalence of serotype 19A declined dramatically [21]. It can be assumed that the implementation of vaccination against pneumococcus has affected the serotype-specific prevalence of pneumococci, including the antibiotic-resistant serotypes, but other factors that have been enhancing the spread of the antibiotic-resistant 19A serotype must be taken into account, as both currently used vaccines (with different 19A coverage) share the market almost equally, and the effect on the replacement by the 19A serotype is therefore limited.

The serotyping of antibiotic-resistant serotypes has shown the increasing prevalence of the 19A serotype following vaccination against pneumococcus; however, this information is not sufficient to identify the origin of the strains. To establish the genetic background of the antibiotic-resistant 19A isolates, we used multi-locus sequence typing (MLST) to identify the clonal lineages associated with antibiotic resistance after the implementation of pneumococcal vaccination. The detailed characteristics of the representative isolates of the major serogroup 19 clones have been further identified by whole-genome sequencing (WGS).

**METHODS**

**Bacterial isolates**

In total, 36 pneumococcal isolates of serotypes 19A (n=26) and 19F (n=10) that were non-susceptible to penicillin and/or macrolides and were collected in 2014 were analysed. Isolates from the blood and cerebrospinal fluid (n=16) were identified among all (n=306) invasive isolates referred to the National Institute of Public Health (NIPH) for antibiotic susceptibility testing and serotyping during national surveillance of IPD. Additional isolates (n=20) were obtained during the surveillance of antibiotic resistance in S. pneumoniae isolates from respiratory tract disease (sinusitis, acute otitis media and community-acquired pneumonia), where only isolates resistant to erythromycin (n=27) are referred to the NIPH.

All isolates were cultured on Columbia agar, and the species identification was confirmed using the deoxycholate test. The serotyping was performed by multiplex PCR using primers and conditions available at the Centers for Disease Control and Prevention (https://www.cdc.gov/streptab/pcr.html). Serotypes were confirmed by the Quellung reaction [22].

**Antibiotic susceptibility**

The minimum inhibitory concentrations (MICs) were determined for penicillin (PEN), cefotaxime (CTX), tetracycline (TET), erythromycin (ERY), clindamycin (CLI), chloramphenicol (CHL) and trimethoprim/sulfamethoxazole (SXT) by the microdilution broth method [23]. The MICs were interpreted according to the criteria of the European Committee on Antimicrobial Susceptibility Testing (EUCAST; www.eucast.org). For epidemiological purposes, the microbiological breakpoints of low-level PEN resistance (MIC range from 0.12 to 2 µg ml⁻¹) and high-level PEN resistance (MIC≥2 µg ml⁻¹) were used. The resistance to macrolides and tetracyclines was confirmed by PCR amplification of the respective genes. Resistance to macrolides was determined by PCR of internal fragments of the mefA and ermB genes according to the previously described protocols [24, 25]. PCR detection of tetracycline resistance was performed by amplification of the 1862-bp fragment from positions 21 to 1882 of the published sequence of the tetM gene [26].

**MLST typing**

DNA was isolated according to the manufacturer’s instructions using a commercial kit (NA2120, Sigma Aldrich) enriched with 250 U ml⁻¹ of mutanolysin (M9901, Sigma Aldrich). Samples were typed according to a standard protocol [27]. Briefly, the internal fragments of seven
housekeeping genes (aroE, gdh, gki, recP, spi, xpt and ddl) were amplified by PCR. The editing and alignment of all the sequences were performed using the publicly available S. pneumoniae MLST database (http://pubmlst.org/spneumoniae/), where new STs were also deposited. Clonal complexes were assigned using the eBURST algorithm (http://eburst.mlst.net). The allelic profiles of the STs of all the isolates were analysed using BioNumerics 7.6 software (Applied Maths, Ghent, East Flanders, Belgium).

WGS library, Illumina sequencing

Four isolates representing the major clones were analysed. The genomic DNA of S. pneumoniae was extracted using the DNA-Sorb-B kit (Sacace Biotechnologies Srl, Como, Italy). The plasmids and chromosomes were sequenced using the Illumina MiSeq platform (Illumina Inc., San Diego, CA, USA). The reads were mapped using the Short Read Sequence Typing 2 (SRST2) tool (version 0.2.0) to assess the presence of virulence and antibiotic resistance genes [28]. The database of virulence genes was obtained from VFDB (http://www.mgc.ac.cn/VFs/), and the database distributed with SRST2 was used to search for resistance genes. The serotypes were determined by mapping reads to the reference cps locus sequences using PneumoCat [29]. The initial reads were quality trimmed using Trimmomatic [30] and assembled via the de Bruijn graph-based de novo assembler SPAdes [31]. The STs of the four de novo assembled genomes were confirmed on http://pubmlst.org/perl/bigsdb/bigsdb.pl?db=pubmlst_spneumoniae_seqdef&page=sequenceQuery. Further analyses of the assembled sequences were performed using BioNumerics 7.6. Gene annotations were carried out by the Bionumerics annotation application using the Taiwan19F-14 element (GenBank accession number CP000921) as the template sequence. The genomic DNA of S. pneumoniae was amplified by PCR. The editing and alignment of all the sequences of the corresponding sequences of S. pneumoniae R6 (accession number NC_003098.1) and compared in detail. The database categorized isolates into six CCs. The largest CC, 19 (see Table 1). eBURST analysis using the whole MLST database revealed 11 different STs among serogroup 19 isolates. The other minor CCs were represented by ST236, the representative of the Taiwan clone, which is frequently associated with the MLSB phenotype, was due to the presence of the tetM genes. All but one of the isolates (serotype 19A, ST 11197) were susceptible to chloramphenicol, and resistance to trimethoprim/sulfamethoxazole was particularly found in 19F-infected patients.

With the exception of two non-viable isolates, all serogroup 19 strains recovered in 2014 that were resistant to erythromycin and/or to penicillin (n=36) were further analysed.

Resistance to macrolides was confirmed in all (n=34) erythromycin-resistant isolates. All of them showed the MLSB phenotype and possessed the ermB gene. Dual-macrolide resistance (ermB and mefA genotypes) was found predominantly in 19F isolates (see Table 1). Resistance to tetracycline, which is frequently associated with the MLSB phenotype, was due to the presence of the tetM genes. All but one of the isolates (serotype 19A, ST 11197) were susceptible to chloramphenicol, and resistance to trimethoprim/sulfamethoxazole was particularly found in 19F isolates.

MLST analysis

MLST analysis revealed 11 different STs among serogroup 19 (see Table 1). eBURST analysis using the whole MLST database categorized isolates into six CCs. The largest CC, including 18 of the 36 isolates (50 %), was represented by ST416 (n=16), ST11198 and ST1756. ST416 is a subgroup founder in CC199 and is related to the Netherlands158-37 clone. All isolates within this CC belonged to serotype 19A (18 of 26 isolates; 69.2 %). The second major CC (CC320), which comprised 10 of the 36 isolates (27.8 %), was represented by ST1464 (n=9) and ST271; both are single-locus variants of ST236, the representative of the Taiwan19F-14 clone. This strain was mainly associated with serotype 19F (9 out of 10 isolates; 90 %), while 1 ST1464 isolate was determined to be in serotype 19A. The other minor CCs were CC230, which is related to the Denmark14-32 clone (four isolates of serotype 19A); CC193, which is related to Greece21-30 (two serotype 19A isolates); CC177, which is related to Portugal19F-21 (a 19F isolate); and CC66 (a 19A isolate).

RESULTS

Antibiotic susceptibility

In 2014, 306 invasive isolates of S. pneumoniae were examined at the National Institute of Public Health, Prague, Czech Republic. Of these, 16 (5.2 %) were non-susceptible to penicillin. Only three isolates belonging to serotype 19F showed high-level resistance to penicillin. The most common serotype among the isolates with low-level resistance (n=13) was serotype 19A (n=4; 30.8 %). Resistance to erythromycin was detected in 22 (7.2 %) isolates and was associated with serotype 19A (n=10; 45.4 %), followed by serotype 19F (n=4; 18.2 %). While serotype 19A was the second most common invasive serotype (n=25; 8.2 %), serotype 19F was far rarer (n=8; 2.6 %). Among the non-invasive respiratory isolates (n=27), resistance to erythromycin was linked with serotypes 19A (n=15; 55.5 %) and 19F (n=6; 22.2 %), and in almost half of the isolates (n=13; 48.1 %) it was combined with decreased susceptibility to penicillin. The median age of patients with serotype 19A was 42 (IQR 65.5–3) years, while it was 63.5 (IQR 70–60.5) years in serotype 19F-infected patients.
<table>
<thead>
<tr>
<th>Isolates</th>
<th>Serotype</th>
<th>Source</th>
<th>Age</th>
<th>MIC (µg ml⁻¹)</th>
<th>ATB resistance genes</th>
<th>CC</th>
<th>ST</th>
<th>Allelic profile</th>
</tr>
</thead>
<tbody>
<tr>
<td>24 679</td>
<td>19A</td>
<td>Blood</td>
<td>70</td>
<td>0.008 0.016 16.0 &gt;4.0 4.0 2.0 0.25</td>
<td>ermB, tetM</td>
<td>199</td>
<td>416</td>
<td>1 13 14 4 17 51 14</td>
</tr>
<tr>
<td>26 584</td>
<td>19A</td>
<td>Blood</td>
<td>60</td>
<td>0.008 0.016 16.0 &gt;4.0 &gt;4.0 4.0 2.0 0.25</td>
<td>ermB, tetM</td>
<td>199</td>
<td>416</td>
<td>1 13 14 4 17 51 14</td>
</tr>
<tr>
<td>27 270</td>
<td>19A</td>
<td>CSF</td>
<td>36</td>
<td>0.016 0.016 16.0 &gt;4.0 &gt;4.0 2.0 0.25</td>
<td>ermB, tetM</td>
<td>199</td>
<td>416†</td>
<td>1 13 14 4 17 51 14</td>
</tr>
<tr>
<td>27 374</td>
<td>19A</td>
<td>Ear</td>
<td>3</td>
<td>0.016 0.016 &gt;16.0 &gt;4.0 4.0 2.0 0.25</td>
<td>ermB, tetM</td>
<td>199</td>
<td>416</td>
<td>1 13 14 4 17 51 14</td>
</tr>
<tr>
<td>27 389</td>
<td>19A</td>
<td>Ear</td>
<td>3</td>
<td>0.016 0.016 16.0 &gt;4.0 &gt;4.0 4.0 2.0 0.25</td>
<td>ermB, tetM</td>
<td>199</td>
<td>416</td>
<td>1 13 14 4 17 51 14</td>
</tr>
<tr>
<td>27 417</td>
<td>19A</td>
<td>Blood</td>
<td>64</td>
<td>0.016 0.016 16.0 &gt;4.0 &gt;4.0 4.0 2.0 0.25</td>
<td>ermB, tetM</td>
<td>199</td>
<td>416</td>
<td>1 13 14 4 17 51 14</td>
</tr>
<tr>
<td>27 491</td>
<td>19A</td>
<td>Ear</td>
<td>3</td>
<td>&lt;0.004 0.016 &lt;0.125 &gt;4.0 &gt;4.0 2.0 0.25</td>
<td>ermB, tetM*</td>
<td>199</td>
<td>416†</td>
<td>1 13 14 4 17 51 14</td>
</tr>
<tr>
<td>27 630</td>
<td>19A</td>
<td>Blood</td>
<td>68</td>
<td>0.016 0.016 16.0 &gt;4.0 &gt;4.0 2.0 0.25</td>
<td>ermB, tetM</td>
<td>199</td>
<td>416</td>
<td>1 13 14 4 17 51 14</td>
</tr>
<tr>
<td>27 775</td>
<td>19A</td>
<td>Ear</td>
<td>Unknown</td>
<td>0.008 0.016 16.0 &gt;4.0 &gt;4.0 2.0 0.25</td>
<td>ermB, tetM</td>
<td>199</td>
<td>416</td>
<td>1 13 14 4 17 51 14</td>
</tr>
<tr>
<td>27 776</td>
<td>19A</td>
<td>Ear</td>
<td>Unknown</td>
<td>0.008 0.016 16.0 &gt;4.0 &gt;4.0 2.0 0.25</td>
<td>ermB, tetM</td>
<td>199</td>
<td>416</td>
<td>1 13 14 4 17 51 14</td>
</tr>
<tr>
<td>27 806</td>
<td>19A</td>
<td>Ear</td>
<td>0</td>
<td>0.016 0.016 16.0 &gt;4.0 &gt;4.0 2.0 0.25</td>
<td>ermB, tetM</td>
<td>199</td>
<td>416</td>
<td>1 13 14 4 17 51 14</td>
</tr>
<tr>
<td>27 844</td>
<td>19A</td>
<td>Ear</td>
<td>0</td>
<td>0.016 0.016 16.0 &gt;4.0 &gt;4.0 2.0 0.25</td>
<td>ermB, tetM</td>
<td>199</td>
<td>416</td>
<td>1 13 14 4 17 51 14</td>
</tr>
<tr>
<td>28 206</td>
<td>19A</td>
<td>Blood</td>
<td>73</td>
<td>0.008 0.03 &lt;0.125 &gt;4.0 2.0 0.5</td>
<td>ermB, tetM*</td>
<td>199</td>
<td>416</td>
<td>1 13 14 4 17 51 14</td>
</tr>
<tr>
<td>28 240</td>
<td>19A</td>
<td>Ear</td>
<td>0</td>
<td>0.008 0.03 &lt;0.125 &gt;4.0 2.0 0.5</td>
<td>ermB, tetM*</td>
<td>199</td>
<td>416</td>
<td>1 13 14 4 17 51 14</td>
</tr>
<tr>
<td>28 258</td>
<td>19F</td>
<td>Sputum</td>
<td>62</td>
<td>0.016 0.016 16.0 &gt;4.0 &gt;4.0 2.0 0.25</td>
<td>ermB, tetM</td>
<td>199</td>
<td>416</td>
<td>1 13 14 4 17 51 14</td>
</tr>
<tr>
<td>28 271</td>
<td>19F</td>
<td>Blood</td>
<td>57</td>
<td>0.008 0.016 &gt;16.0 &gt;4.0 &gt;4.0 4.0 0.5</td>
<td>ermB, mefA, tetM</td>
<td>320</td>
<td>271†</td>
<td>4 16 19 15 6 20 26</td>
</tr>
<tr>
<td>27 722</td>
<td>19A</td>
<td>Sputum</td>
<td>67</td>
<td>2.0 1.0 16.0 &gt;4.0 &gt;4.0 2.0 &gt;4.0</td>
<td>ermB, mefA, tetM</td>
<td>320</td>
<td>1464</td>
<td>4 16 19 15 6 20 106</td>
</tr>
<tr>
<td>24 238</td>
<td>19F</td>
<td>CSF</td>
<td>73</td>
<td>4.0 2.0 8.0 &gt;4.0 &gt;4.0 4.0 &gt;4.0</td>
<td>ermB, mefA, tetM</td>
<td>320</td>
<td>1464</td>
<td>4 16 19 15 6 20 106</td>
</tr>
<tr>
<td>24 633</td>
<td>19F</td>
<td>Sputum</td>
<td>56</td>
<td>4.0 2.0 16.0 &gt;4.0 &gt;4.0 4.0 &gt;4.0</td>
<td>ermB, mefA, tetM</td>
<td>320</td>
<td>1464†</td>
<td>4 16 19 15 6 20 106</td>
</tr>
<tr>
<td>24 870</td>
<td>19F</td>
<td>Sputum</td>
<td>65</td>
<td>4.0 2.0 16.0 &gt;4.0 &gt;4.0 2.0 &gt;4.0</td>
<td>ermB, mefA, tetM</td>
<td>320</td>
<td>1464</td>
<td>4 16 19 15 6 20 106</td>
</tr>
<tr>
<td>24 993</td>
<td>19F</td>
<td>Sputum</td>
<td>62</td>
<td>4.0 2.0 16.0 &gt;4.0 &gt;4.0 4.0 &gt;4.0</td>
<td>ermB, mefA, tetM</td>
<td>320</td>
<td>1464</td>
<td>4 16 19 15 6 20 106</td>
</tr>
<tr>
<td>27 721</td>
<td>19F</td>
<td>Sputum</td>
<td>60</td>
<td>2.0 1.0 16.0 &gt;4.0 &gt;4.0 2.0 &gt;4.0</td>
<td>ermB, mefA, tetM</td>
<td>320</td>
<td>1464</td>
<td>4 16 19 15 6 20 106</td>
</tr>
<tr>
<td>27 723</td>
<td>19F</td>
<td>Sputum</td>
<td>61</td>
<td>2.0 1.0 16.0 &gt;4.0 &gt;4.0 2.0 &gt;4.0</td>
<td>ermB, mefA, tetM</td>
<td>320</td>
<td>1464</td>
<td>4 16 19 15 6 20 106</td>
</tr>
<tr>
<td>27 992</td>
<td>19F</td>
<td>Blood</td>
<td>67</td>
<td>4.0 2.0 16.0 &gt;4.0 &gt;4.0 2.0 &gt;4.0</td>
<td>ermB, mefA, tetM</td>
<td>320</td>
<td>1464</td>
<td>4 16 19 15 6 20 106</td>
</tr>
<tr>
<td>28 205</td>
<td>19F</td>
<td>Sputum</td>
<td>73</td>
<td>4.0 2.0 16.0 &gt;4.0 &gt;4.0 4.0 &gt;4.0</td>
<td>ermB, mefA, tetM</td>
<td>320</td>
<td>1464</td>
<td>4 16 19 15 6 20 106</td>
</tr>
<tr>
<td>24 493</td>
<td>19A</td>
<td>Blood</td>
<td>21</td>
<td>0.25 0.25 16.0 &gt;4.0 &gt;4.0 2.0 0.125</td>
<td>ermB, tetM</td>
<td>230</td>
<td>230</td>
<td>12 19 2 17 6 22 14</td>
</tr>
<tr>
<td>28 258</td>
<td>19A</td>
<td>Sputum</td>
<td>69</td>
<td>0.5 0.125 16.0 &gt;4.0 0.5 2.0 0.125</td>
<td>ermB, tetM</td>
<td>230</td>
<td>230</td>
<td>12 19 2 17 6 22 14</td>
</tr>
</tbody>
</table>

Table 1. Characteristics of serogroup 19 isolates (n=36) obtained in the Czech Republic in 2014.
### Table 1.

<table>
<thead>
<tr>
<th>Isolates</th>
<th>Serotype</th>
<th>Source</th>
<th>MIC (µg ml(^{-1}))</th>
<th>ST</th>
<th>Allelic profile</th>
<th>CC</th>
<th>ST</th>
<th>PMEN clone</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>Age</strong> PEN CTX TET TET</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>ermB, tetM</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>aroE gdh gki recP spi xpt ddl</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>27,14</td>
<td>19A</td>
<td>Blood</td>
<td>61 2.0 1.0 16.0 &gt;4.0</td>
<td>19A</td>
<td>219 276 2 19 17 6 22 14</td>
<td>230</td>
<td>276 2 19 17 6 22 14</td>
<td></td>
</tr>
<tr>
<td>25,833</td>
<td>19A</td>
<td>Blood</td>
<td>60 0.5 0.25 &gt;16.0 &gt;4.0</td>
<td>19A</td>
<td>220 2013 12 19 17 6 20 14</td>
<td>230 2013 12 19 17 6 20 14</td>
<td></td>
<td></td>
</tr>
<tr>
<td>23,049</td>
<td>19A</td>
<td>Blood</td>
<td>4 0.3 0.3 &gt;16.0 &gt;4.0</td>
<td>19A</td>
<td>193 2083 8 20 11 16 1 26</td>
<td>193 2083 8 20 11 16 1 26</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20,804</td>
<td>19F</td>
<td>Blood</td>
<td>79 0.6 0.6 &gt;16.0 &gt;4.0</td>
<td>19F</td>
<td>197 179 7 14 40 12 1 14</td>
<td>197 179 7 14 40 12 1 14</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20,872</td>
<td>19A</td>
<td>Ear</td>
<td>5 &lt;0.004 &lt;0.008 &gt;16.0 &gt;4.0</td>
<td>19A</td>
<td>66 1197 1 5 41 10 616 8</td>
<td>66 1197 1 5 41 10 616 8</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| 21,102   | 19A      | Ear    | 5 <0.004 <0.008 >16.0 >4.0 | 19A | 213 6002, showing 99.99 % similarity to the \(Tn6002\) complete sequence (GenBank accession number AY898750.1), was found in 19A isolates (CC199). This transposon carried two antibiotic resistance genes: \(tetM\) and \(ermB\). However, one 19A isolate (27491) carrying the \(tetM\) gene was found to be phenotypically susceptible due to the deletion of a 26-bp-long segment (spanning from nucleotide position 16 298 to 16 323 of the \(tetM\) gene), leading to a frameshift mutation. The other transposon was identified as \(Tn2010\), showing 99.99 % similarity to the \(Tn2010\) complete sequence (GenBank accession number AB426620.1). This transposon has been found in both 19F isolates (CC320), and aside from \(tetM\) and \(ermB\), it also carries the \(mefE/mel\) operon.

### Comparison of PBP genes

The PBP sequences of \(ppb2x\), \(ppb2b\) and \(ppb1a\) of penicillin-susceptible 19A isolates were highly identical (99.0 to 100 % similarity) to those of the R6 strain (see Fig. 1). The \(Ppb\) sequences of penicillin-resistant 19F isolates were additionally compared to the corresponding sequences of
the Taiwan19F-14 and Hungary19A-6 reference strains and the multidrug-resistant A026 pneumococcal strain (GenBank accession number CP006844). The Pbp1a sequences of the two 19F isolates were identical. Moreover, they were 100% similar to the pbp1a sequence of the Taiwan19F-14 reference strain. The Pbp2x sequence of the 25 137 isolate was also highly similar to the pbp2x sequence of the Taiwan19F-14 reference strain (99% similarity), but differed from that of the other 19F isolate (94% similarity). The PBP2x of the 25 137 isolate (ST271) possessed the unique amino acid (aa) substitutions M339F, E378A, M400T and Y595F, which are distinct from those in Taiwan19F-14 but identical to those reported in the ST271 clinical isolates from Hong Kong [37]. Isolate 24 238 (ST1464) possessed an additional five aa substitutions (P268T, D278N, N501K, K505E and A507T) compared to Taiwan19F-14, but none of them has yet been identified as playing a role in resistance to betalactams. Compared to the ST271 isolate, ST1464 lacks three mutations (M339F, M400T and Y595F) associated with cefotaxime resistance [38]. Both isolates contained mutations within the S337TMK motif: T338A in ST1464 and T338A plus M339F in the ST271 isolate. The Pbp2b sequences of both 19F isolates showed the lowest similarity to those of the Taiwan19F-14 strain (91% similarity), while they were also distantly related to each other (94% similarity). Comparison of the pbp2b sequences with the R6 sequence revealed the presence of different mosaic blocks in the two 19F isolates. The aa sequence of the 25 137 isolate (ST271) was identical to the sequences of the ST271 isolates of the 19F serotype from Hong Kong. The aa sequence of the other isolate (24 238, ST1464) contained relatively short mosaic blocks at positions 333 to 538, which is highly similar to the corresponding Taiwan19F-14 reference aa sequence, but differed from ST271 in three substitutions. The ST1464 isolate possessed two additional mutations (V383I and D497Y) but lacked the E369D mutation.
conferring high-level resistance to cefotaxime. At positions 561 to 582, the isolates differed in nine aa substitutions (absent in ST1464); however, at positions 592 to 676, the isolates were identical and possessed 16 aa changes that have been reported before in resistant Polish isolates of the Poland19F-16 clone and in multidrug-resistant isolates of serogroup 19 from Hong Kong [37, 39].

**DISCUSSION**

Despite the relatively stable low prevalence of antibiotic resistance in invasive pneumococci, an increase in antibiotic-resistant serotype 19A has been observed in the Czech Republic. MLST analysis identified ST416 as the dominant emerging genotype, which was in contrast to previous studies that reported a post-vaccine clonal expansion of the 19A capsular variant of the Taiwan19F-14 clone, but in agreement with findings from other European countries, where clonal expansion of ST416 has been observed [9, 40–42]. It is estimated that the successful spread of serotype 19A is due to its genetic diversity, and various lineages of serotype 19A have emerged in the post-vaccine era [9]. The main drivers of the increasing prevalence of serotype 19A are antibiotic selection pressure and a high propensity for capsular switching. The pathogenicity of pneumococci has been attributed to various structures, most of which are located on its surface [43]. Numerous in vitro studies have identified different pneumococcal proteins as possible protein vaccine candidates [44–46]. Pneumococcal surface proteins are involved in bacterial fitness and pathogen–host interactions. Pneumococcal are highly plastic bacteria, as they are able to adapt the expression of certain virulence factors to host niches during various stages of infection [47]. However, the prevalence of some of those surface proteins seems to be clonally related. It has been suggested that the presence of pilus 1 promotes adherence and thereby increases the competitive capacity of piliated strains [48]. Previous studies have also provided evidence for an association between antibiotic-resistant clones and the presence of pilus 1 [48–51]. In our study, all of the WGS-analysed isolates carried pilus 1. The presence of pilus 1 in 19A isolates of ST416 is of interest, since group founder ST199 isolates are pilus-negative. It is likely that the acquisition of pilus 1 could promote a clonal expansion of this genotype to a significant degree. On the other hand, another adhesin, PsrP, was only present in 19A isolates of ST416. PsrP, which acts as the lung cell adhesin, was found to be significantly associated with serotypes with higher invasive disease potential (including the 19A serotype), and it was hypothesized that PsrP is most probably linked to enhanced virulence of those serotypes [52, 53]. Selva et al. have shown a negative correlation of the simultaneous prevalence of PsrP and pilus 1, suggesting that the production of extremely large proteins might be metabolically expensive and that individual strains either do not support the expression of both proteins, or the function of both adhesins is redundant [36]. However, based on the results of our study, it seems that both virulence factors act synergistically and jointly increase the fitness of the ST416 clonal lineage, which constituted at least 40% of the serotype 19A population among IPD in 2014. Moreover, the overall prevalence of the 19A serotype increased from 2.7% in 2010 to 9.9% in 2015, with 19A being the second most frequently reported invasive serotype in the Czech Republic [54]. A tentative explanation is that the clonal expansion of 19A ST416/CC199, which is becoming more common than 19F ST1464/CC320, is due to the contribution of the co-presence of several serotype-independent factors, which makes a capsular type more prone to occupy the niche left by PCV10 serotypes.

The non-susceptibility to betalactams was mainly associated with serotype 19F of CC320, represented by its single locus variants (SLVs), ST1464 and ST271. These SLVs differed from ST320 in the ddl gene, which is highly variable in penicillin-resistant isolates due to the proximity of the pbp2b gene, which is affected by interspecies recombination exchanges driven by penicillin usage [55]. Penicillin non-susceptibility in pneumococci is mediated by the recombination of pbp genes (namely pbp1a, pbp2b and pbp2x) leading to aa substitutions at or close to the active site of the transpeptidase domains [56, 57]. The development of penicillin resistance in pneumococci is driven by gene transfer events from related species, especially Streptococcus mitis or Streptococcus oralis [58, 59]. PBP2x and PBP2b are considered to be primary resistance determinants conferring low-level resistance, and an alteration of those PBPs is a prerequisite for the emergence of high-level resistance, together with a concomitant alteration of PBP1a [60]. Although both of the two penicillin-resistant isolates had a unique PBP profile, transpeptidase domains that were identical or related to those previously reported in pneumococci were detected in both isolates [33, 37, 39, 61]. The PBP1a sequence was identical to that of the Taiwan19F-14 strain. Moreover, the same PBP1a aa sequences have been described previously in clinical isolates of serogroup 19 (ST271 and ST320) [37]. It seems that this PBP1a variant is a rather stable characteristic of the Taiwan19F-14 clone, contributing to its typical phenotype. The PBP2x sequence of the ST271 isolate has also been identified in Hong Kong isolates of the corresponding serotype and ST [37]. The aa substitutions in PBP2x, such as T338A, M339F and M400T, were found to be responsible for cefotaxime resistance [38]. The presence of these aa substitutions, together with additional changes (E378A and Y595F), are important for the emergence of high-level resistance to cefotaxime [37, 62]. The presence of mutations was in line with the observed high level of resistance to cefotaxime in the isolate of ST271, while the ST1464 isolate, where three of these aa changes (M339F, M400T and Y595F) were absent, showed low-level resistance (cefotaxime MIC of 2 μg ml−1). Both ST271 and ST1464 possessed aa substitutions of PBP2b involved in enzyme activity (T446A, A619G and Q628E). The Pbp2b sequences contained aa substitutions that were absent in Taiwan19F-14. Whereas ST271 was identical to the ST271 isolates of the 19F serotype reported in Hong Kong, ST1464 lacked 12 aa substitutions inside a block identified
previously in the resistant *S. mitis* strain B22 (EMBL accession number AY187721). The patterns of the two *pbp2b* were highly similar to those of variants IV (ST271) and V (ST1464) of *pbp2b*, respectively, shown in Polish isolates of the Poland 2003-16 clone [39]. Our results demonstrate the diversity of *pbp* genes, which occurs even at the subclone level, and corroborate the necessity for a detailed analysis of *pbp* polymorphism.

In conclusion, after pneumococcal vaccination, new prevailing clones of serotypes 19A and 19F have been identified among antibiotic-resistant invasive pneumococci in the Czech Republic. The success of those clones is probably linked to the presence of specific characteristics (namely pilus 1), but other factors, such as post-vaccine serotype replacement or antibiotic consumption, may have favoured their further spread.

**Funding information**

This work was supported by the Czech Health Research Council, Ministry of Health of the Czech Republic, grant no. 16-27109A and by MH CZ – DRO (National Institute of Public Health – NIPH, 75010330).

**Acknowledgements**

This publication made use of the Streptococcus pneumoniae MLST website (https://pubmlst.org/spneumoniae/) located at the University of Oxford (Jolley & Maiden 2010, BMC Bioinformatics, 11: 595). The development of this site has been funded by the Wellcome Trust.

**Conflicts of interest**

The authors declare that there are no conflicts of interest.

**Ethical statement**

This is a retrospective study in which the isolates were used without patient identifiers and hence patient consent has not been obtained.

**References**


27. Enright MC, Spratt BG. A multilocus sequence typing scheme for
Streptococcus pneumoniae: identification of clones associated with

SRST2: Rapid genomic surveillance for public health and hospital

et al. Whole genome sequencing of Streptococcus pneumoniae:
development, evaluation and verification of targets for serogroup
and serotype prediction using an automated pipeline. PeerJ 2016;
4:e2677.


SPAdes: a new genome assembly algorithm and its applications

sequence of Streptococcus pneumoniae strain A026, a clinical mul-
tidrug-resistant isolate carrying Tn90. Genome Announc 2013;1;
et al.

33. Contreras-Martel C, Dahout-Gonzalez C, Martins AS, Kotnik M, Dessen A. PBP active site flexibility as the key mechanism for β-

34. Pérez-Dorado I, Galan-Bartual S, Hermoso JA. Pneumococcal
surface proteins: when the whole is greater than the sum of its

New adhesin functions of surface-exposed pneumococcal pro-

36. Selva L, Ciruela P, Blanchette E, Amo E, Pallares R et al. Prevalence and clonal distribution of
Streptococcus pneumoniae serogroup 19 CC320/271 clone with
high-level resistance to third-generation cephalosporins. J Infect Dis

37. Carapito R, Chesnel L, Vernet T, Zapun A. Pneumococcal β-lactam
resistance due to a conformational change in penicillin-

2b, and PBP 1a in isolates of two Streptococcus pneumoniae
clonal groups, Poland 279–16 and Poland 59–20. Antimicrob Agents

cine genetic structure of Streptococcus pneumoniae serotype 19A
1995.


41. van der Linden M, Reinert RR, Kern W, Imohl M. Epidemiology of serotype 19A isolates from invasive pneumococcal disease in


43. Briles DE, Hollingshead S, Brooks-Walter A, Nabors GS, Ferguson L et al. The potential to use PsPα and other pneumococ-

antigens and their relationship with pneumococcal carriage in

45. Argondizzo APC, Rocha-de-Souza CM, De Almeida Santiago M, Galler R, Reis JN et al. Pneumococcal predictive proteins selected
by microbial genomic approach are serotype cross-reactive and
bind to host extracellular matrix proteins. Appl Biochem Biotechnol
2017;182:1518–1539.

46. Overweg K, Pericone CD, Verhoef GG, Weiser JN, Meiring HD et al. Differential protein expression in phenotypic variants of

47. Sjöstöm K, Blomberg C, Fernebro J, Dagerhamn J, Morefeldt E et al. Clonal success of pilated pneumocillin nonsusceptible pneumo-

Streptococcus pneumoniae isolates from Israel. Clin Microbiol Infect

49. Sadowy E, Kuch A, Gniadkowski M, Hryniwcz W. Expansion and evolution of the Streptococcus pneumoniae Spain7–ST156 clonal
1727.

50. Aguilar SI, Serrano I, Pinto FR, Melo-Cristino J, Ramirez M. The presence of the pilus locus is a clonal property among pneumo-

51. Shivshankar P, Sanchez C, Rose LF, Orihuela CJ. The Streptococ-
cus pneumoniae-adhesin PspR binds to Keratin 10 on lung cells.

52. Muñoz-Almagro C, Selva L, Sanchez CJ, Esteva C, de Sevilla MF et al. PspR, a protective pneumococcal antigen, is highly prevalent
in children with pneumonia and is strongly associated with clonal

53. Kozakova J, Sebestova H, Krizova P. Invasive pneumococcal dis-
ease in the Czech Republic in 2015. Bull Centre Epid Microbiol

54. Enright MC, Spratt BG. Extensive variation in the ddi gene of penicillin-resistant Streptococcus pneumoniae results from a hitch-
hiking effect driven by the penicillin-binding protein 2b gene. Mol

55. Grebe T, Hakenbeck R. Penicillin-binding proteins 2b and 2x of
Streptococcus pneumoniae are primary resistance determinants for
different classes of beta-lactam antibiotics. Antimicrob Agents

proteins as resistance determinants in clinical isolates of Strepto-

Acquisition of five high-Mr penicillin-binding protein variants dur-
ing transfer of high-level β-lactam resistance from Streptococcus
1840.

58. Dowson CG, Coffey TJ, Kell C, Whiteley RA. Evolution of penicillin
resistance in Streptococcus pneumoniae: the role of Streptococcus
mitis in the formation of a low affinity PBP2 in S. pneumoniae. Mol

59. Sauerbier J, Maurer P, Rieger M, Hakenbeck R. Streptococcus
pneumoniae R6 interspecies transformation: genetic analysis of
penicillin resistance determinants and genome-wide recombina-

60. Ramalingam J, Vennila J, Subbiah P. Computational studies on the resistance of penicillin-binding protein 2B (PBP2B) of wild-
type and mutant strains of Streptococcus pneumoniae against β-

61. Smith AM, Klugman KP. Amino acid mutations essential to pro-
duction of an altered PBP 2X conferring high-level β-lactam resis-
tance in a clinical isolate of Streptococcus pneumoniae. Antimicrob